Hemophilia | Current Treatment: Physician Insights | US | 2018

Prior to the launch of Hemlibra, the hemophilia market consisted solely of factor-based products. The use of factor concentrate is highly varied; brand-dependent dosing and infusion frequencies, layered on top of patient differences and preferences, result in a complex management landscape. DRG anticipates that the next ten years will be exciting in the hemophilia space. Pipeline activity is high, and new agents offer compelling clinical profiles; however, currently available factor-based agents are entrenched, and we anticipate they will continue to experience significant uptake.


  • Are physicians intending to use Hemlibra prophylactically or on demand, and is this decision age-dependent? What do physicians forecast Hemlibra’s patient share will be in five years’ time?
  • What is the 2017 branded patient share of factor concentrates such as Shire’s Adynovate and CSL’s Idelvion? What are the anticipated changes in prescribing patterns once gene therapy or the aTFPI class launches?
  • Are physicians using the same brand differently for prophylaxis versus on demand?
  • How are inhibitor patients currently managed in terms of treatment strategy and brands used (e.g., NovoSeven, FEIBA)?


Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.


United States


Hemophilia Current Treatment: Physician Insights is a primary market research study evaluating physician self-reported prescribing and treatment practices in hemophilia. E-mail invitations were sent to hematologists to participate in an online survey. 75 hematologists completed the survey. The survey took approximately 30 minutes to complete. Fieldwork occurred in April 2018.

To qualify, respondents met the following screening criteria:

  • Board-certified in hematology.
  • In practice for a minimum of 2 years and a maximum of 35 years.
  • Do not practice in Vermont.
  • More than 75% of professional time spent in clinical practice.

After meeting the screening criteria, respondents were directed to an online survey, and respondents were paid an honorarium for their participation. Statistical significance testing was done when appropriate, including anticipated versus current allocations, subgroups, and brands.


Aptevo Therapeutics, Bayer HealthCare, Bioverativ, Chugai, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Shire


Advate, Adynovate, Afstyla, Alprolix, Benefix, Eloctate, FEIBA, Helixate, Hemlibra, Idelvion, Ixinity, Kogenate, Kovaltry, NovoEight, NovoSeven, Nuwiq, Rixubis, Xyntha

Login to access report